CG Oncology (NASDAQ:CGON) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of CG Oncology (NASDAQ:CGON) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $75.00 target price on the stock.

Several other research analysts also recently commented on CGON. UBS Group assumed coverage on CG Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $60.00 target price on the stock. Bank of America reiterated a “buy” rating and set a $65.00 price objective on shares of CG Oncology in a research report on Tuesday, October 8th. Roth Mkm initiated coverage on shares of CG Oncology in a research report on Tuesday, August 27th. They set a “buy” rating and a $65.00 price target on the stock. Royal Bank of Canada assumed coverage on CG Oncology in a research note on Monday, September 23rd. They set an “outperform” rating and a $66.00 target price for the company. Finally, Roth Capital upgraded shares of CG Oncology to a “strong-buy” rating in a report on Tuesday, August 27th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $63.88.

CG Oncology Stock Performance

Shares of CGON stock opened at $36.98 on Tuesday. CG Oncology has a twelve month low of $25.77 and a twelve month high of $50.23. The stock’s fifty day simple moving average is $36.87 and its 200 day simple moving average is $34.80.

Insider Buying and Selling at CG Oncology

In other news, Director Hong Fang Song sold 650,455 shares of the stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $35.36, for a total value of $23,000,088.80. Following the completion of the sale, the director now owns 586,982 shares in the company, valued at $20,755,683.52. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Hedge Funds Weigh In On CG Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of CGON. Amalgamated Bank boosted its position in CG Oncology by 107.6% in the third quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock worth $61,000 after purchasing an additional 840 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new position in CG Oncology in the first quarter valued at about $102,000. California State Teachers Retirement System purchased a new stake in shares of CG Oncology during the 1st quarter worth approximately $103,000. Rhumbline Advisers raised its holdings in shares of CG Oncology by 13.0% in the 2nd quarter. Rhumbline Advisers now owns 34,229 shares of the company’s stock worth $1,081,000 after purchasing an additional 3,940 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in CG Oncology by 2.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 266,787 shares of the company’s stock valued at $8,422,000 after purchasing an additional 6,899 shares during the last quarter. Hedge funds and other institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.